PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
April 24, 2026European Journal of Preventive Cardiology0 citationsOpen Access

Effect Of Angiopoietin-Like Protein 3 Inhibitors On Lipid Profile: A Meta-Analysis

Effect of angiopoietin-like protein 3 inhibitors on lipid profile and other biomarkers: a meta-analysis of randomized controlled trials

View Full Paper
Ask AI
Bookmark
Share

Why the study?

Inhibition of ANGPTL3 has been proposed to reduce residual cardiovascular risk, prompting a comprehensive evaluation of the metabolic effects of ANGPTL3 inhibitors.

Do ANGPTL3 inhibitors improve lipid profiles and other biomarkers compared to placebo?

Comparison

ANGPTL3 inhibitors vs placebo

Design

Meta-analysis of randomized controlled trials

Key result

ANGPTL3 inhibition significantly reduced triglycerides (-47.1%), LDL-C (-21.6%), and remnant cholesterol (-72.7%) compared to placebo.

Authors

SXSining XieFGFederica GalimbertiEOElena Olmastroni

Discussion

Loading...

Member takes

Overview

Positions ANGPTL3 inhibition as a potent tool for mixed dyslipidemia; leaves open.

Key Points

  • This meta-analysis aims to evaluate the metabolic effects of angiopoietin-like protein 3 (ANGPTL3) inhibitors on lipid profiles.
  • Systematic search of databases for randomized controlled trials comparing ANGPTL3 inhibitors with placebo.
  • Pooled analysis of percentage changes in lipid profiles across studies.
  • Subgroup analysis based on the mechanism of action of the inhibitors.
  • Significant reductions in triglycerides by 47.1%, LDL-C by 21.6%, and total cholesterol by 32.8%.
  • Marked decrease in ANGPTL3 protein levels by 70.7% with no significant effect on high-sensitivity CRP.
  • Subgroup analyses showed varying effectiveness among different types of ANGPTL3 inhibitors for specific lipids.

Study Design

Type

Meta-Analysis (n=1,254)

Structured PICO

Do ANGPTL3 inhibitors improve lipid profiles and other biomarkers compared to placebo?

P
Population
1,254 participants from 9 RCTs
I
Intervention
ANGPTL3 inhibitors (monoclonal antibodies [evinacumab], antisense oligonucleotides [vupanorsen], and small interfering RNAs [zodasiran and solbinsiran])
C
Comparator
Placebo
O
Outcome
Percentage change from baseline in triglycerides (TG), LDL-C, apolipoprotein B (ApoB), non-HDL-C, HDL-C, total cholesterol (TC), VLDL-C, ApoA1, ApoC3, Lp(a), remnant cholesterol (RC), ANGPTL3 and C-reactive protein (CRP)surrogate

ANGPTL3 inhibition provides broad lipid-lowering benefits, with particularly marked reductions in triglyceride-rich lipoproteins.

Cite This Study

Xie et al. (2026) conducted a meta-analysis in Cardiovascular risk (n=1,254). ANGPTL3 inhibitors vs. Placebo was evaluated on Percentage change from baseline in lipid profile and other biomarkers. ANGPTL3 inhibition significantly reduced triglycerides (-47.1%), LDL-C (-21.6%), and remnant cholesterol (-72.7%) compared to placebo.

synapsesocial.com/papers/69eb0961553a5433e34b3e21https://doi.org/10.1093/eurjpc/zwag230
View Full Paper
Ask AI
Bookmark
Share